Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes

Myelodisplastic syndrome (MDS) includes a spectrum of hematological alterations that have in common the progressive evolution of a monoclonal population of hemopoietic cells, arising from an initial genetic insult, to a preleukemic status and eventually to overt acute leukemia.1,2,3